Clinical Trials Logo

Atopic Dermatitis clinical trials

View clinical trials related to Atopic Dermatitis.

Filter by:

NCT ID: NCT05531188 Completed - Atopic Dermatitis Clinical Trials

Efficacy Evaluation and Cutaneous Acceptability of the Lipikar Med Product on Subjects With Atopic Dermatitis

Start date: March 1, 2021
Phase:
Study type: Observational

In this study, we will test the tolerance of a topical product and its efficacy in reducing the atopy crisis duration and severity. The product will be tested alone, in children and adults with acute mild to moderate AD i.e as an alternative to alternative treatments, over 6 weeks.

NCT ID: NCT05530707 Completed - Atopic Dermatitis Clinical Trials

Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer

Start date: September 5, 2022
Phase: N/A
Study type: Interventional

A unicentric, blind, non-comparative clinical study to evaluate the efficacy of a moisturizer in reducing clinical symptons of atopic dermatites in children through clinical, subjective and instrumental evaluations.

NCT ID: NCT05470114 Completed - Atopic Dermatitis Clinical Trials

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

Start date: May 19, 2022
Phase: Phase 2
Study type: Interventional

This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection. Some people in the trial will instead receive Dupixent® which is an approved treatment for moderate to severe AD. Dupixent® is also given by subcutaneous injection. The main aim of this clinical trial is to investigate which changes in biomarkers in the skin are caused by LEO 138559 and Dupixent®. The trial includes a screening phase of up to 4 weeks, followed by a treatment period of 16 weeks, and a safety follow-up period of 16 weeks.

NCT ID: NCT05467046 Completed - Atopic Dermatitis Clinical Trials

Clinical Relevance of Scratching and Sleep in Atopic Dermatitis

Start date: August 3, 2022
Phase:
Study type: Observational

Atopic Dermatitis (AD), otherwise known as (atopic) eczema, is a chronic relapsing inflammatory skin disease. For difficult-to-treat AD, treatment options are limited. A better understanding of the underlying immunological cause, led to development of new, targeted therapies. For evaluating effectiveness and making treatment decisions for these new therapies, only 2 subjective methods exist: 1. clinical scores (AD-severity scored by a physician using structured scoring system), 2. questionnaires (completed by AD-patients). Therefore, an objective AD-severity assessment method might provide benefits for clinical practice. In this study, it is evaluated whether scratching and sleep parameters, obtained with a smartwatch worn by AD-patients, provide added value for clinical practice in dermatology. The usability of this smartwatch system is evaluated by AD-patients.

NCT ID: NCT05461456 Completed - Psoriasis Clinical Trials

Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%

ATOFEX-1
Start date: April 1, 2022
Phase: Phase 1
Study type: Interventional

The investigational lotion is envisaged as an short- and long term "Ease & Prevent" monotherapy for adults and children with mild to moderate eczema. With itch representing the most burdensome symptom in eczema, the main objectives with the lotion is fast and efficient itch relief, high tolerability, and high short- and long term safety. This phase 1 study aims to monitor skin tolerability, and how much of the active compound that is absorbed to the bloodstream.

NCT ID: NCT05432596 Completed - Atopic Dermatitis Clinical Trials

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Start date: May 11, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2b study to determine the safety, tolerability, pharmacokinetic (PK), and efficacy of ATI-1777 in patients 12 to 65 years old with mild to severe Atopic Dermatitis. Eligible participants will apply either ATI-1777 or Vehicle Topical Solution once daily or twice daily for 4 weeks.

NCT ID: NCT05383378 Completed - Atopic Dermatitis Clinical Trials

A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis

Start date: August 30, 2022
Phase: Phase 1
Study type: Interventional

This is a multi-center, Phase 1b, double-blind, placebo-controlled, SAD and MAD, first-in-human study in subjects with mild to severe AD receiving si-544. The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo. Initially, 2 sentinel subjects will be treated (randomized to placebo or si-544) in each cohort.

NCT ID: NCT05375955 Completed - Atopic Dermatitis Clinical Trials

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Start date: September 26, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you apply it on your skin. The study medicine is in ointment form. This study is seeking participants who If they have Atopic Dermatitis (AD): - Have a diagnosis for at least 3 months - Have a diagnosis of mild or moderate disease assessed using Investigator's Global Assessment (IGA) - Have percent Body Surface Area (%BSA) covering 5% up to 40% - A Peak Pruritus Numerical Rating Scale (PP-NRS) average score of ≥2 during the screening period If they have plaque psoriasis (PsO): - Have a diagnosis for at least 6 months - Have a diagnosis of mild, moderate, or severe disease assessed using Physician's Global Assessment (PGA) - Have percent Body Surface Area (%BSA) covering 2% up to 20% All participants in this study will receive either 0.01% PF-07038124, 0.03% PF-07038124, or a vehicle ointment. In addition, some participants with PsO will receive 0.06% PF- PF-07038124. Participants will not know which dose level they have received. The participants will be randomly assigned to each dose group. PF-07038124 ointment will be applied topically to affected areas once daily. We will compare the experiences of people receiving the different dose levels of the ointment to those who receive the vehicle ointment. This will help us determine if PF-07038124 ointment is safe and effective. Participants will take part in this study for approximately 21 weeks. Participants will apply the study medicine once daily for 12 weeks followed by a safety follow-up period of 4-5 weeks from last application of study medicine to last visit.

NCT ID: NCT05372003 Completed - Atopic Dermatitis Clinical Trials

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

Start date: August 9, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils, their secreted cytokines (interleukin-4), and metabolism in human health and disease states such as obesity and insulin resistance.

NCT ID: NCT05276323 Completed - Atopic Dermatitis Clinical Trials

Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

A randomized, open-label trial comparing Medihoney Derma Cream to Hydrocortisone 1% cream. Children between the ages of 2-18 years old diagnosed with mild to moderate atopic dermatitis with an IGA (Investigator Global Assessment) score of 2-3, and a BSA (Body Surface Area) score of 1%-10% were included.